Mass-Screening of Curarimimetic Neurotoxin Antagonists

1990 ◽  
Author(s):  
Jakob Schmidt
Keyword(s):  
Mass Screening

Transient galactosemia detected by neonatal mass screening

1999 ◽  
Vol 41 (3) ◽  
pp. 281-284 ◽  
Author(s):  
HIROAKI Ono ◽  
HIDEO Mawatari ◽  
NOBUYUKI Mizoguchi ◽  
TAKAATSU Eguchi ◽  
Nobuo Sakura1 and Mochiyuki Hamakawa
Keyword(s):  
Mass Screening

The Concepts of Prevalence and Incidence as Applied to the Study of Development and Duration of Disease

1968 ◽  
Vol 7 (02) ◽  
pp. 111-117 ◽  
Author(s):  
M. Kashgahian
Keyword(s):  
Mass Screening ◽  
Disease Process ◽  
Incidence Data ◽  
Disease States ◽  
History Of ◽  
Duration Of Disease ◽  
Process Methodology

The proper use of prevalence and incidence data can result in an effective way to study the history of the disease process. Methodology is given whereby the progression, duration and transition of diseases can be elucidated. Prevalence and incidence have been redefined and used in an unconventional way in view of new types of data which are being generated by mass screening projects for disease which are able to discover presymptomatic and preclinical disease states.

EVALUATION OF MASS SCREENING FOR BREAST CANCER

1992 ◽  
Vol 42 (3) ◽  
pp. 261-272
Author(s):  
TSUNEHIRO ISHIDA ◽  
TAKAO YOKOE ◽  
YUICHI IINO ◽  
TETSUO OGAWA ◽  
TOSHIKAZU ISHIKITA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mass Screening

Shifting from nasopharyngeal swab to sputum for mass screening of COVID-19 patients in India- A public health perspective

2020 ◽  
Vol 23 (19) ◽  
Author(s):  
Nishantadeb Ghatak ◽  
Sheikh Mohd Saleem ◽  
Roy Rillera Marzo ◽  
Sudip Bhattacharya ◽  
Amarjeet Singh
Keyword(s):  
Public Health ◽  
Mass Screening ◽  
Nasopharyngeal Swab ◽  
Public Health Perspective

PROSPECTS OF ARTIFICIAL INTELLIGENCE IN CARRYING OUT THE ONCOLOGICAL COMPONENT OF MEDICAL EXAMINATION OF THE POPULATION

2019 ◽  
Vol 65 (2) ◽  
pp. 234-237
Author(s):  
Vyacheslav Cherenkov ◽  
A. Petrov ◽  
I. Gulkov ◽  
A. Kostyukov
Keyword(s):  
Artificial Intelligence ◽  
Early Diagnosis ◽  
Mass Screening ◽  
Malignant Tumors ◽  
Risk Groups ◽  
Modern World ◽  
Pilot Program ◽  
Urgent Problem ◽  
Gender And Age ◽  
Group Version

Diagnosis of malignant tumors is an urgent problem of the modern world. Early diagnosis depends on General practitioners. The doctor should conduct a systematic examination of the patient regularly, taking into account the risk groups, gender and age. With mass screening, signs of dysplasia or an early focus, developing cancer can «slip away» [1]. Optimization of analysis and examination algorithms is required, which is not always possible for one person. Positive application of the digital program with elements of imaging in Oncology, we were able to create such a class of tasks for the preliminary subjective-objective survey of patients in three versions: with a widescreen screen and consoles for patients (group version up to 15 or more patients), interactive (touch) and tablet. The results of the survey are sent through the accepted channels to the doctor with recommendations for further examination, and the patient is given a coupon. The pilot program showed that the system of such robotic technologies in the future can replace the oncologist in its development to artificial intelligence at the stage of the primary link.

A Novel Strategy for SARS-CoV-2 Mass-Screening Using Quantitative Antigen Testing of Saliva

2020 ◽  
Author(s):  
Isao Yokota ◽  
Peter Y. Shane ◽  
Kazufumi Okada ◽  
Yokota Unoki ◽  
Yichi Yang ◽  
...  
Keyword(s):  
Mass Screening ◽  
Novel Strategy ◽  
Antigen Testing

scholarly journals NESTROFT—A Cost-Effective Mass Screening Tool for the Detection of β-Thalassemia Carrier Status in Anemic Pregnant Women: A Step Toward Reducing the National Disease Burden

2021 ◽  
Author(s):  
Manasi Gosavi ◽  
Ramesh Chavan ◽  
M. B. Bellad
Keyword(s):  
Pregnant Women ◽  
Effective Mass ◽  
Mass Screening ◽  
Predictive Value ◽  
Screening Tool ◽  
Hematological Parameters ◽  
False Negative ◽  
Cost Effective ◽  
Mean Corpuscular Hemoglobin ◽  
Carrier Status

Abstract Introduction β-Thalassemias are inherited hemoglobinopathies commonly encountered in practice. With chances of a promising cure being rare, the prevention of births with this disorder should assume priority, especially in low-resource countries. This can be achieved by the implementation of a mass screening program that is reliable and, at the same time, cost-effective. Objectives This study focuses on the utility of Naked Eye Single Tube Red Cell Osmotic Fragility Test (NESTROFT) as a mass screening tool to detect thalassemia carriers. Hematological parameters that may predict carrier status were also evaluated. Materials and Methods Hemoglobin estimation was performed on all consented pregnant women. If the patient was found to have hemoglobin < 11 g/dL, the blood sample was subjected to other routine hematological tests along with peripheral smear examination. NESTROFT was performed using 0.36% saline solution. Confirmation was done using high-performance liquid chromatography (HPLC). Statistical Analysis Data obtained were tabulated using version 21 of the Statistical Package for Social Sciences. Means, standard deviations, and percentages were used to describe the sample. Chi-square test and Students’ “t” test were used to identify differences between the groups. Results Of 441 pregnant women enrolled, 206 were found to be anemic. Nineteen (9.2%) of the anemic pregnant women were detected to be carriers of hemoglobinopathies. Among the hematological parameters, mean red blood cell count and reticulocyte count were higher, while mean corpuscular hemoglobin concentration was lower in carriers. Also, carriers were more likely to present with microcytic hypochromic anemia. NESTROFT showed a sensitivity of 84.21%, specificity of 96.25%, a positive predictive value of 69.56%, and a negative predictive value of 98.36%. A false-positive result was seen in 3.74% of the tests, while a false negative result was seen in 15.78% of the tests. Conclusions NESTROFT (0.36%) can be used as a simple and cost-effective mass screening tool for the detection of carrier status. This should be followed by confirmation using HPLC or hemoglobin electrophoresis.

Sign in / Sign up

Export Citation Format

Share Document